These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 7880938

  • 1. Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa.
    Ghigo E, Arvat E, Gianotti L, Nicolosi M, Valetto MR, Avagnina S, Bellitti D, Rolla M, Müller EE, Camanni F.
    Biol Psychiatry; 1994 Nov 15; 36(10):689-95. PubMed ID: 7880938
    [Abstract] [Full Text] [Related]

  • 2. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E.
    Int J Obes Relat Metab Disord; 1995 Feb 15; 19(2):108-12. PubMed ID: 7735336
    [Abstract] [Full Text] [Related]

  • 3. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1997 Oct 15; 47(4):495-500. PubMed ID: 9404449
    [Abstract] [Full Text] [Related]

  • 4. Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa.
    Gianotti L, Rolla M, Arvat E, Belliti D, Valetto MR, Ferdeghini M, Ghigo E, Müller EE.
    Biol Psychiatry; 1999 Feb 01; 45(3):334-9. PubMed ID: 10023511
    [Abstract] [Full Text] [Related]

  • 5. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1989 Feb 01; 68(2):290-3. PubMed ID: 2493023
    [Abstract] [Full Text] [Related]

  • 6. Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release: studies in normal and acromegalic subjects.
    Massara F, Ghigo E, Demislis K, Tangolo D, Mazza E, Locatelli V, Müller EE, Molinatti GM, Camanni F.
    Neuroendocrinology; 1986 Feb 01; 43(6):670-5. PubMed ID: 3093909
    [Abstract] [Full Text] [Related]

  • 7. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging.
    Ghigo E, Goffi S, Arvat E, Nicolosi M, Procopio M, Bellone J, Imperiale E, Mazza E, Baracchi G, Camanni F.
    Acta Endocrinol (Copenh); 1990 Aug 01; 123(2):169-73. PubMed ID: 2220258
    [Abstract] [Full Text] [Related]

  • 8. Growth hormone secretion in Alzheimer's disease: studies with growth hormone-releasing hormone alone and combined with pyridostigmine or arginine.
    Ghigo E, Nicolosi M, Arvat E, Marcone A, Danelon F, Mucci M, Franceschi M, Smirne S, Camanni F.
    Dementia; 1993 Aug 01; 4(6):315-20. PubMed ID: 8136894
    [Abstract] [Full Text] [Related]

  • 9. Aspects of the neuroendocrine control of somatotropic function in calorically restricted dogs and patients with eating disorders: studies with cholinergic drugs.
    Müller EE, Rolla M.
    Psychiatry Res; 1996 Apr 16; 62(1):51-63. PubMed ID: 8739115
    [Abstract] [Full Text] [Related]

  • 10. Cholinergic modulation of growth hormone responses to growth hormone-releasing hormone in uraemic patients on peritoneal dialysis.
    Díez JJ, Iglesias P, Selgas R, Bajo MA, Aguilera A.
    Clin Endocrinol (Oxf); 2000 Nov 16; 53(5):587-93. PubMed ID: 11106919
    [Abstract] [Full Text] [Related]

  • 11. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women.
    Arvat E, Cappa M, Casanueva FF, Dieguez C, Ghigo E, Nicolosi M, Valcavi R, Zini M.
    J Clin Endocrinol Metab; 1993 Feb 16; 76(2):374-7. PubMed ID: 8432781
    [Abstract] [Full Text] [Related]

  • 12. Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Further evidence for a somatostatin suppressing effect of arginine.
    Ghigo E, Bellone J, Mazza E, Imperiale E, Procopio M, Valente F, Lala R, De Sanctis C, Camanni F.
    Clin Endocrinol (Oxf); 1990 Jun 16; 32(6):763-7. PubMed ID: 1974484
    [Abstract] [Full Text] [Related]

  • 13. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R, Valente F, Dieguez C, Zini M, Procopio M, Portioli I, Ghigo E.
    J Clin Endocrinol Metab; 1993 Sep 16; 77(3):616-20. PubMed ID: 8103770
    [Abstract] [Full Text] [Related]

  • 14. The role of cholinergic tone in modulating the growth hormone response to growth hormone-releasing hormone in normal man.
    Giustina A, Bossoni S, Bodini C, Doga M, Girelli A, Buffoli MG, Schettino M, Wehrenberg WB.
    Metabolism; 1991 May 16; 40(5):519-23. PubMed ID: 2023538
    [Abstract] [Full Text] [Related]

  • 15. A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging.
    Ghigo E, Goffi S, Arvat E, Imperiale E, Boffano GM, Valetto MR, Mazza E, Santi I, Magliona A, Boghen MF.
    J Endocrinol Invest; 1992 Oct 16; 15(9):665-70. PubMed ID: 1479149
    [Abstract] [Full Text] [Related]

  • 16. Effects of direct and indirect acetylcholine receptor agonists on growth hormone secretion in humans.
    Mazza E, Ghigo E, Boffano G, Valetto M, Maccario M, Arvat E, Bellone J, Procopio M, Müller EE, Camanni F.
    Eur J Pharmacol; 1994 Mar 11; 254(1-2):17-20. PubMed ID: 8206111
    [Abstract] [Full Text] [Related]

  • 17. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS, Scanlon MF, Peters JR.
    Clin Endocrinol (Oxf); 1993 Feb 11; 38(2):149-57. PubMed ID: 8094648
    [Abstract] [Full Text] [Related]

  • 18. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L, Marziani E, Manzoni P, Arvat E, Valetto MR, Gianotti L, Ghigo E, Chiumello G.
    Dement Geriatr Cogn Disord; 1998 Feb 11; 9(2):78-81. PubMed ID: 9524798
    [Abstract] [Full Text] [Related]

  • 19. The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome.
    Arvat E, Gianotti L, Ragusa L, Valetto MR, Cappa M, Aimaretti G, Ramunni J, Grottoli S, Camanni F, Ghigo E.
    Dementia; 1996 Feb 11; 7(5):288-92. PubMed ID: 8872421
    [Abstract] [Full Text] [Related]

  • 20. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion.
    Corsello SM, Tofani A, Della Casa S, Sciuto R, Rota CA, Colasanti S, Bini A, Barini A, Barbarino A.
    Acta Endocrinol (Copenh); 1992 Feb 11; 126(2):113-6. PubMed ID: 1543015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.